- Home
- KALA vs MDAI Comparison
KALA vs MDAI Comparison
Compare KALA & MDAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KALA
- MDAI
- Stock Information
- Founded
- KALA 2009
- MDAI 2013
- Country
- KALA United States
- MDAI United States
- Employees
- KALA N/A
- MDAI N/A
- Industry
- KALA Biotechnology: Pharmaceutical Preparations
- MDAI Medical/Dental Instruments
- Sector
- KALA Health Care
- MDAI Health Care
- Exchange
- KALA Nasdaq
- MDAI Nasdaq
- Market Cap
- KALA 27.3M
- MDAI 28.3M
- IPO Year
- KALA 2017
- MDAI N/A
- Fundamental
- Price
- KALA $6.64
- MDAI $1.95
- Analyst Decision
- KALA Strong Buy
- MDAI Strong Buy
- Analyst Count
- KALA 2
- MDAI 2
- Target Price
- KALA $15.00
- MDAI $4.75
- AVG Volume (30 Days)
- KALA 108.1K
- MDAI 616.5K
- Earning Date
- KALA 03-28-2025
- MDAI 03-26-2025
- Dividend Yield
- KALA N/A
- MDAI N/A
- EPS Growth
- KALA N/A
- MDAI N/A
- EPS
- KALA N/A
- MDAI N/A
- Revenue
- KALA N/A
- MDAI $27,264,000.00
- Revenue This Year
- KALA N/A
- MDAI $61.78
- Revenue Next Year
- KALA N/A
- MDAI N/A
- P/E Ratio
- KALA N/A
- MDAI N/A
- Revenue Growth
- KALA N/A
- MDAI 44.52
- 52 Week Low
- KALA $4.21
- MDAI $0.82
- 52 Week High
- KALA $11.20
- MDAI $3.25
- Technical
- Relative Strength Index (RSI)
- KALA 39.29
- MDAI 45.75
- Support Level
- KALA $6.50
- MDAI $1.86
- Resistance Level
- KALA $8.65
- MDAI $2.25
- Average True Range (ATR)
- KALA 0.90
- MDAI 0.15
- MACD
- KALA -0.43
- MDAI -0.00
- Stochastic Oscillator
- KALA 2.98
- MDAI 37.50
About KALA KALA BIO Inc.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
About MDAI Spectral AI Inc.
Spectral AI Inc is an AI company, focused on predictive medical diagnostics. Spectral is devoting substantially all of its efforts towards the research and development of its DeepView System, an internally developed MSI device that has designated FDA BDD status. Its DeepView System uses proprietary algorithms to distinguish between damaged and healthy human tissue invisible to the naked eye, providing Day One healing assessments in seconds. The Company's output is specifically engineered to allow the physician to make a more accurate, timely, and informed decision regarding the treatment of the patient's wound.